cm310
mAbexperimental
Clinical trial activity
32 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
21
Phase 3
9
Phase 4
1
Earliest trial started Sep 3, 2019 (NCT06161090)
Timeline
Indications
Studied for
- Asthma · Phase 2/Phase 3
- Biological Therapy · Phase 4
- Biomarkers · Phase 4
- Dermatitis, Atopic · Phase 3
- Healthy Volunteers · Phase 1
- Nasal Polyps · Phase 2
- Neoplasms · Phase 3
- Prurigo · Phase 3
- Pruritus · Phase 2
- Pulmonary Disease, Chronic Obstructive · Phase 2/Phase 3
- Rhinitis, Allergic · Phase 3
- Rhinitis, Allergic, Seasonal · Phase 2
- Sinusitis · Phase 4
- Squamous Cell Carcinoma of Head and Neck · Phase 1
Mechanism of action
- Programmed cell death protein 1INHIBITOR
Programmed cell death protein 1 inhibitor
- Interleukin-4 receptor subunit alphaINHIBITOR
IL4R inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095324 ↗
- ChEMBLCHEMBL4650516 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07240376 | N/A | Nov 25, 2025 | Huazhong University of Science and Technology, Wuhan University, Xiamen University |
| NCT07210554 | Phase 3 | Nov 11, 2025 | Government of China, Peking University |
| NCT07143864 | N/A | Sep 15, 2025 | Chongqing Medical University |
| NCT07040072 | Phase 1 | Jun 30, 2025 | Capital Medical University, Keymed Biosciences Co.Ltd, Sinocelltech Ltd. |
| NCT07009470 | N/A | Feb 10, 2025 | Huazhong University of Science and Technology |
| NCT06801353 | Phase 4 | Feb 1, 2025 | Capital Medical University |
| NCT06525597 | Phase 2 | Sep 30, 2024 | Capital Medical University, Keymed Biosciences Co.Ltd |
| NCT06547333 | Phase 2/Phase 3 (Phase 3) | Sep 13, 2024 | Shijiazhuang Pharma Group (CSPC) |
| NCT06495229 | Phase 3 | Aug 30, 2024 | Keymed Biosciences Co.Ltd |
| NCT06424470 | Phase 3 | Jul 30, 2024 | Keymed Biosciences Co.Ltd |
| NCT06277765 | Phase 3 | May 30, 2024 | Keymed Biosciences Co.Ltd, Peking University |
| NCT06171048 | Phase 1 | Apr 30, 2024 | Anhui Medical University, Keymed Biosciences Co.Ltd |
| NCT06116565 | Phase 2 | Mar 30, 2024 | Keymed Biosciences Co.Ltd |
| NCT06162507 | Phase 1/Phase 2 (Phase 2) | Mar 30, 2024 | Keymed Biosciences Co.Ltd |
| NCT06171074 | Phase 2 | Mar 30, 2024 | Capital Medical University, Keymed Biosciences Co.Ltd |
| NCT05908721 | Phase 2 | Oct 30, 2023 | Keymed Biosciences Co.Ltd |
| NCT05908032 | Phase 3 | Sep 30, 2023 | Keymed Biosciences Co.Ltd |
| NCT05761028 | Phase 2/Phase 3 (Phase 3) | Apr 28, 2023 | Shijiazhuang Pharma Group (CSPC) |
| NCT05702450 | Phase 1 | Mar 22, 2023 | Keymed Biosciences Co.Ltd, Peking University |
| NCT05715320 | Phase 2 | Mar 10, 2023 | Keymed Biosciences Co.Ltd |
Showing 20 of 32 trials
Page 1 / 2
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Keymed Biosciences Co.Ltd | For profit | 24 | 23 | 3 | 2019 |
| Capital Medical University | Academic/Hospital | 6 | 3 | 4 | 2021 |
| Peking University | Academic/Hospital | 4 | 0 | 2 | 2022 |
| Huazhong University of Science and Technology | Academic/Hospital | 2 | 2 | 1 | 2025 |
| Shijiazhuang Pharma Group (CSPC) | For profit | 2 | 2 | 1 | 2023 |
| Anhui Medical University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Chongqing Medical University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Government of China | Government | 1 | 1 | 1 | 2025 |
| Sinocelltech Ltd. | For profit | 1 | 0 | 1 | 2025 |
| Wuhan University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Xiamen University | Academic/Hospital | 1 | 0 | 1 | 2025 |
11 organizations
Page 1 / 1